U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C16H14O5
Molecular Weight 286.2794
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GUACETISAL

SMILES

COC1=C(OC(=O)C2=C(OC(C)=O)C=CC=C2)C=CC=C1

InChI

InChIKey=HSJFYRYGGKLQBT-UHFFFAOYSA-N
InChI=1S/C16H14O5/c1-11(17)20-13-8-4-3-7-12(13)16(18)21-15-10-6-5-9-14(15)19-2/h3-10H,1-2H3

HIDE SMILES / InChI
Molecular Formula C16H14O5
Molecular Weight 286.2794
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Guacetisal (Broncaspin) is a bronchomucotropic synthesized by the Bayer Italia S.p.A. Research Laboratories. It is obtained from the esterification of acetylsalicylic acid with guaiacol. Guacetisal was used for the treatment of chronic bronchitis and other inflammatory diseases of the respiratory tract. Guacetisal, used rectally, proved to be a valuable instrument for anti-inflammatory and anti-cough treatment in acute diseases of the airways in infancy.

Originator

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
PubMed

PubMed

TitleDatePubMed
[Broncaspin in respiratory diseases in pediatrics. Clinical contribution].
1981 Feb 28
[Clinical study of a preparation with bronchomucotropic activity: guacetisal].
1981 Feb 28
Patents

Patents

CN103102271A
1
CN106966899A
1

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Also used orally: a Broncaspin suspension was administered for an average of 6-7 days (1/2 teaspoonful twice a day to patients up to 3 yr old; 1 teaspoonful twice a day to those over 3) in the treatment of acute febrile diseases of the upper airways in 16 male and 14 female children aged 5 months to 5 and 3/12 yr. https://www.ncbi.nlm.nih.gov/pubmed/7243038
Broncaspin (guacetisal) has been administered rectally to 42 children suffering from inflammatory diseases of the upper and lower airways, most cases being complicated by bronchospasm. Treatment involving a dose of 1-2 suppositories of 0.5 g/die up to six years of age, and 2 suppositories/die after the sixth year always produced a good antipyretic and anti-cough effect.
Route of Administration: Rectal
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:29:12 UTC 2023
Edited
by admin
on Fri Dec 15 15:29:12 UTC 2023
Record UNII
T6EKB9V2O2
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
GUACETISAL
INN   MART.   WHO-DD  
INN  
Official Name English
guacetisal [INN]
Common Name English
Guacetisal [WHO-DD]
Common Name English
GUACETISAL [MART.]
Common Name English
PRONTOMUCIL
Brand Name English
O-METHOXYPHENYL SALICYLATE ACETATE
Common Name English
ASPIRIN GUAIACOL ESTER
MI  
Common Name English
ASPIRIN GUAIACOL ESTER [MI]
Common Name English
Classification Tree Code System Code
WHO-ATC N02BA14
Created by admin on Fri Dec 15 15:29:12 UTC 2023 , Edited by admin on Fri Dec 15 15:29:12 UTC 2023
NCI_THESAURUS C257
Created by admin on Fri Dec 15 15:29:12 UTC 2023 , Edited by admin on Fri Dec 15 15:29:12 UTC 2023
WHO-VATC QN02BA14
Created by admin on Fri Dec 15 15:29:12 UTC 2023 , Edited by admin on Fri Dec 15 15:29:12 UTC 2023
Code System Code Type Description
ChEMBL
CHEMBL2105097
Created by admin on Fri Dec 15 15:29:12 UTC 2023 , Edited by admin on Fri Dec 15 15:29:12 UTC 2023
PRIMARY
DRUG CENTRAL
1333
Created by admin on Fri Dec 15 15:29:12 UTC 2023 , Edited by admin on Fri Dec 15 15:29:12 UTC 2023
PRIMARY
FDA UNII
T6EKB9V2O2
Created by admin on Fri Dec 15 15:29:12 UTC 2023 , Edited by admin on Fri Dec 15 15:29:12 UTC 2023
PRIMARY
MESH
C023557
Created by admin on Fri Dec 15 15:29:12 UTC 2023 , Edited by admin on Fri Dec 15 15:29:12 UTC 2023
PRIMARY
MERCK INDEX
m2111
Created by admin on Fri Dec 15 15:29:12 UTC 2023 , Edited by admin on Fri Dec 15 15:29:12 UTC 2023
PRIMARY Merck Index
SMS_ID
100000084240
Created by admin on Fri Dec 15 15:29:12 UTC 2023 , Edited by admin on Fri Dec 15 15:29:12 UTC 2023
PRIMARY
INN
4512
Created by admin on Fri Dec 15 15:29:12 UTC 2023 , Edited by admin on Fri Dec 15 15:29:12 UTC 2023
PRIMARY
EVMPD
SUB07968MIG
Created by admin on Fri Dec 15 15:29:12 UTC 2023 , Edited by admin on Fri Dec 15 15:29:12 UTC 2023
PRIMARY
ECHA (EC/EINECS)
259-663-1
Created by admin on Fri Dec 15 15:29:12 UTC 2023 , Edited by admin on Fri Dec 15 15:29:12 UTC 2023
PRIMARY
EPA CompTox
DTXSID40204060
Created by admin on Fri Dec 15 15:29:12 UTC 2023 , Edited by admin on Fri Dec 15 15:29:12 UTC 2023
PRIMARY
PUBCHEM
68749
Created by admin on Fri Dec 15 15:29:12 UTC 2023 , Edited by admin on Fri Dec 15 15:29:12 UTC 2023
PRIMARY
WIKIPEDIA
Guacetisal
Created by admin on Fri Dec 15 15:29:12 UTC 2023 , Edited by admin on Fri Dec 15 15:29:12 UTC 2023
PRIMARY
NCI_THESAURUS
C65821
Created by admin on Fri Dec 15 15:29:12 UTC 2023 , Edited by admin on Fri Dec 15 15:29:12 UTC 2023
PRIMARY
CAS
55482-89-8
Created by admin on Fri Dec 15 15:29:12 UTC 2023 , Edited by admin on Fri Dec 15 15:29:12 UTC 2023
PRIMARY
DRUG BANK
DB13538
Created by admin on Fri Dec 15 15:29:12 UTC 2023 , Edited by admin on Fri Dec 15 15:29:12 UTC 2023
PRIMARY
Related Record Type Details
Structure of GUACETISAL
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966